Interview with Patrick Lucy, President and CEO of Lykan Bioscience

This is an interview with Patrick Lucy, President and CEO of Lykan Bioscience. Lykan is an innovative cell therapy-focused contract development and manufacturing organization (CDMO) headquartered in Hopkinton, MA. In this interview, we discuss the vision of Lykan Bioscience, its innovative and agile approach to CDMO services, and the company’s future goals. 

A new automated iPSC high-throughput induction system to induce thousands of iPSC lines simultaneously: To be presented at ISSCR 2022 Annual Meeting

Palo Alto, California, June 14, 2022 – I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based GMP cell manufacturing CDMO and personal iPSC banking provider, announced that the company has succeeded in developing a propriety automated iPSC high-throughput induction system to induce thousands of iPSC lines simultaneously. There are various automated cell processing/expansion systems in the market today, but this is the first high-throughput, automated cell processing system that is capable of inducing iPSCs from somatic cells.

Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology

SEATTLE and PESSAC, France / June 10th, 2022 – Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies, and TreeFrog Therapeutics, a biotech company aimed at making safer, more efficient and more affordable cell therapies based on iPSCs, announced that they have entered into a collaboration to evaluate Umoja’s iPSC platform within TreeFrog’s C-Stem™ technology for scalable expansion and immune cell differentiation in bioreactors.

Kimera Society Announces its 1st American Exosomes and RNA Conference

Kimera® Society, a biotechnology non-profit research organization, is holding its first inaugural American Exosomes and RNA scientific, research and medical conference. This event, which will bring together some of the top scientists, researchers and clinicians from around the world, will be held September 16-18, 2022, in Miami Beach, Florida at the Palms Hotel. The three-day conference will discuss the latest research, science and clinical applications, as well as the latest innovations in diagnostics and therapeutic protocols for exosome and RNA science and medicine.

Interview with Dr. Nianwei Lin, Co-Founder and President of iXCells Biotechnologies

Founded in 2014 and headquartered in San Diego, CA, iXCells Biotechnologies is a cell biology and cell technology company specializing in pre-clinical drug discovery solutions. iXCells provides primary cells and iPSC derived cells, custom iPSC services, and functional bioassay development and execution, among other products and services. In this interview with Nianwei Lin, Co-Founder and President of iXCells Biotechnologies, we discuss the company’s product pipeline, innovative drug discovery solutions, CRO services, and its future goals.

Axol Bioscience Announces CiPA-Validated Human iPSC-Derived Ventricular Cardiomyocytes

Axol Bioscience Ltd., an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation. Using this assay, the cells were shown to be suitable for measuring cardiotoxicity, offering scientists a robust cardiac model for drug discovery and screening.

What Is An RMAT? List of Publicly Announced RMAT Designations (66)

To date, 66 RMAT (Regenerative Medicine Advanced Therapy) designations have been publicly announced. However, the FDA states it has received 187 requests and issued 70, which means that a handful are not yet public knowledge. Sponsors of cell and gene therapies are eligible to obtain an RMAT designation from the U.S. FDA if their product is intended to treat serious or life-threatening diseases and there is preliminary clinical evidence that it can address unmet medical needs.

Aruna Bio Announces Issuance of a New Composition of Matter Patent Covering Neural Exosomes in Japan

Aruna Bio, Inc., leader in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, announced that the Japan UPSC UENO Patent Office has issued a patent, No. 7075594, to Aruna Bio and the University of Georgia Research Foundation allowing broad claims on the composition of neural exosomes and their use as a therapeutic for neurological diseases and disorders.

Clean Meat Market: Stem Cell Derived "Clean Meat" Attracts Billionaires

Although not yet popular, lab-grown meat is fast becoming a real alternative to its farm-grown counterpart as billionaire entrepreneurs and industry heavyweights invest into start-ups from across the nascent field of “cellular agriculture”. Produced via stem cells derived from cows, pigs, fish, sheep, or other livestock, the emerging clean meat industry has the potential to transform the global food market and create a new trillion dollar industry in the process.

Defined Bioscience to Develop Stem Cells and iPSC-Derived Tissue for Life Science and Cultivated Meat Applications

San Diego, CA, June 15, 2022 — Defined Bioscience, a life science tools company pioneering the development of next generation ingredients for cell culture, announced the formation of its scientific advisory board (SAB). The SAB is comprised of a distinguished group of academic and industry experts who will advise the Defined Bioscience team on the development and commercialization of cell culture reagents, growth medium and kits to consistently grow high quality stem cells and iPSC-derived tissue with applications in life science and cultivated meat.

Who Discovered Stem Cells? The Answers Revealed

Who discovered stem cells is a question worthy of exploration. While Robert Hooke first discovered the concept of cells themselves, the discovery of stem cells is usually credited to Drs. James Till & Ernset McCulloch. For several hundred years, researchers have known that the human body is comprised of trillions of tiny structures. Known as cells, these structures can only be seen at a microscopic level. 

The Pipeline for iPSC-Derived Cell Therapeutics in 2022

Despite progress involving the use of iPSCs within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. The targets for iPSC-derived therapies include any diseases or disorders for which there are no other viable treatments and where there is a need to repair or replace dysfunctional tissue. Today, the following companies and organizations are forging the path toward iPSC-derived cell therapeutics.

Cord Blood Industry Consolidation Escalates in 2022

The global cord blood industry experienced strong growth from the early 1990’s through the late 2000’s, during which time more than 450 cord blood banking companies emerged worldwide. Approximately half of those companies owned their own labs, while the others were marketing entities or sub-contractors of storage space. Starting about ten years ago, the market abruptly changed course, entering a period of aggressive consolidation.

OrganaBio Initiates GMP Manufacturing Operations at its New Cell Therapy Manufacturing Facility

MIAMI, June 20, 2022 - OrganaBio, LLC, announces initiation of GMP manufacturing operations at its new cell therapy manufacturing facility, launching a new paradigm in contract and development manufacturing. Acknowledging the need for custom solutions for therapeutics developers, the company will not only leverage its tissue supply chains to manufacture clinical grade tissue and cellular raw materials derived from perinatal tissues and adult apheresis products for partners, but will also offer contract-, self-, and hybrid-manufacturing options within the facility.

[NEW] Global Exosome Market - Market Size, Forecasts, Trials, & Trends, 2022

Exosome technologies have been developing rapidly over the past few years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine. To characterize the rapidly expanding exosome market, BioInformant has released a global strategic report that explores growing demand for exosome therapeutics, diagnostics, research tools, and manufacturing technologies. The report reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials, as well as market size figures with projections through 2030.

To access other market insights about CAR-T cell therapy, MSCs, iPSCs, cord blood, and beyond, explore the BioInformant Shop.

*Want to advertise in this newsletter? Contact us at Info@BioInformant.com.